NASDAQ:ACOR

Acorda Therapeutics Stock Forecast, Price & News

$7.97

+1.27 (+18.96 %)

(As of 01/19/2021 12:00 AM ET)

Add

Compare

Today's Range

$6.97

Now: $7.97▼

$8.40

50-Day Range

$0.69

MA: $4.34▼

$6.70

52-Week Range

$2.53

Now: $7.97▼

$15.30

Volume2.78 million shs

Average Volume4.23 million shs

Market Capitalization$63.72 million

P/E Ratio1.44

Dividend YieldN/A

Beta0.75

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

MarketRank^™

Overall MarketRank^™

1.38 out of 5 stars

2.8 Analyst's Opinion

Consensus Rating
Acorda Therapeutics has received a consensus rating of Hold. The company's average rating score is 1.67, and is based on no buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $23.67, Acorda Therapeutics has a forecasted upside of 196.9% from its current price of $7.97.
Amount of Analyst Coverage
Acorda Therapeutics has received no research coverage in the past 90 days.

2.2 Community Rank

Outperform Votes
Acorda Therapeutics has received 431 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Acorda Therapeutics has received 543 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Acorda Therapeutics has received 55.75% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote “Outperform” if you believe ACOR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACOR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Acorda Therapeutics does not currently pay a dividend.
Dividend Growth
Acorda Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Acorda Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.80% of the stock of Acorda Therapeutics is held by insiders.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Acorda Therapeutics are expected to decrease in the coming year, from ($9.34) to ($14.61) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Acorda Therapeutics is 1.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.08.
Price to Earnings Ratio vs. Sector
The P/E ratio of Acorda Therapeutics is 1.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.58.
Price to Book Value per Share Ratio
Acorda Therapeutics has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:ACOR

Previous Symbol

CUSIP00484M10

CIK1008848

Webwww.acorda.com

Phone914-347-4300

Employees344

Debt

Debt-to-Equity Ratio0.52

Current Ratio1.09

Quick Ratio0.88

Price-To-Earnings

Trailing P/E Ratio1.44

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$192.41 million

Price / Sales0.33

Cash Flow$34.65 per share

Price / Cash Flow0.23

Book Value$38.82 per share

Price / Book0.21

Profitability

EPS (Most Recent Fiscal Year)($11.94)

Net Income$-272,970,000.00

Net Margins29.71%

Return on Equity-8.60%

Return on Assets-3.51%

Miscellaneous

Outstanding Shares7,995,000

Market Cap$63.72 million

Next Earnings Date2/11/2021 (Estimated)

OptionableOptionable

$7.97

+1.27 (+18.96 %)

(As of 01/19/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.

Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

How has Acorda Therapeutics' stock been impacted by Coronavirus?

Acorda Therapeutics' stock was trading at $6.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ACOR shares have increased by 31.5% and is now trading at $7.97.
View which stocks have been most impacted by COVID-19.

Is Acorda Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Acorda Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACOR, but not buy additional shares or sell existing shares.
View analyst ratings for Acorda Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Acorda Therapeutics?

Wall Street analysts have given Acorda Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Acorda Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Acorda Therapeutics' next earnings date?

Acorda Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Acorda Therapeutics.

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) posted its earnings results on Sunday, November, 8th. The biopharmaceutical company reported ($1.38) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($2.82) by $1.44. The biopharmaceutical company had revenue of $53.09 million for the quarter, compared to the consensus estimate of $29.39 million. Acorda Therapeutics had a negative return on equity of 8.60% and a net margin of 29.71%.
View Acorda Therapeutics' earnings history.

When did Acorda Therapeutics' stock split? How did Acorda Therapeutics' stock split work?

Shares of Acorda Therapeutics reverse split before market open on Monday, January 4th 2021. The 1-6 reverse split was announced on Thursday, December 31st 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 31st 2020. An investor that had 100 shares of Acorda Therapeutics stock prior to the reverse split would have 17 shares after the split.

What price target have analysts set for ACOR?

3 equities research analysts have issued 1 year price objectives for Acorda Therapeutics' stock. Their forecasts range from $6.00 to $35.00. On average, they anticipate Acorda Therapeutics' stock price to reach $23.67 in the next twelve months. This suggests a possible upside of 196.9% from the stock's current price.
View analysts' price targets for Acorda Therapeutics or view Wall Street analyst' top-rated stocks.

Are investors shorting Acorda Therapeutics?

Acorda Therapeutics saw a decrease in short interest in the month of December. As of December 31st, there was short interest totaling 2,610,000 shares, a decrease of 68.6% from the December 15th total of 8,320,000 shares. Based on an average daily trading volume, of 6,690,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 5.5% of the company's shares are sold short.
View Acorda Therapeutics' Short Interest.

Who are some of Acorda Therapeutics' key competitors?

Some companies that are related to Acorda Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Novavax (NVAX).
View all of ACOR's competitors.

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the following people:

Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 64, Pay $827.95k)
Mr. David Lawrence, CTO, Chief of Bus. Operations & Principal Accounting Officer (Age 62, Pay $480.9k)
Ms. Jane Wasman, Consultant (Age 64, Pay $1.85M)
Ms. Lauren M. Sabella, Chief Commercial Officer (Age 59, Pay $490.07k)
Dr. Burkhard Blank, Chief Medical Officer and Head of R&D (Age 65, Pay $662.5k)
Ms. Felicia Vonella, VP of Investor Relations
Mr. Andrew Mayer J.D., Sr. VP, Deputy Gen. Counsel & Corp. Sec.
Ms. Tierney Saccavino, Exec. VP of Corp. Communications
Ms. Denise J. Duca, Exec. VP of HR
Dr. Andrew R. Blight, Chief Scientific Officer Emeritus (Age 69)

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How do I buy shares of Acorda Therapeutics?

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $7.97.

How big of a company is Acorda Therapeutics?

Acorda Therapeutics has a market capitalization of $63.72 million and generates $192.41 million in revenue each year. The biopharmaceutical company earns $-272,970,000.00 in net income (profit) each year or ($11.94) on an earnings per share basis. Acorda Therapeutics employs 344 workers across the globe.

What is Acorda Therapeutics' official website?

The official website for Acorda Therapeutics is www.acorda.com.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.

This page was last updated on 1/19/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here